New vaccine aims to stop pancreatic cancer return
NCT ID NCT07612930
First seen Jun 13, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This program offers a personalized vaccine called PCNAT-01 to patients with pancreatic cancer who have had surgery and finished chemotherapy. The vaccine is made from each patient's unique tumor proteins and is given as shots to train the immune system to fight any remaining cancer cells. The goal is to lower the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PCNAT-01 (personalized tumor neoantigen peptide vaccine with Poly-ICLC)
What this could lead to
If it works, this could help prevent pancreatic cancer from coming back after surgery and chemotherapy.
What could go wrong
This is an early expanded access program, not a full trial, so results are uncertain. The vaccine is personalized and may not work for everyone, and there are risks like side effects from the injections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.